You are here: Industry Insights > Tanfanercept

News List

Harbour BioMed Doses First Patient in Tanfanercept Trial americanpharmaceuticalreview
March 19, 2021
Harbour BioMed announced the dosing of the first patient in the Phase III clinical trial of its global investigational tumor necrosis factor (TNF) receptor-1 fragment-based drug Tanfanercept (HBM9036) for adult patients with moderate-to-severe dry eye ...
Harbour BioMed Announces Dosing of First Patient in Tanfanercept Phase III Clinical Trial prnasia
March 12, 2021
Harbour BioMed today announced the dosing of the first patient in the Phase III clinical trial of its new global investigational tumor necrosis factor (TNF) receptor-1 fragment-based drug Tanfanercept (HBM9036) for adult patients with ...
Harbour BioMed Will Present Results From Its Phase II Clinical Trial with Tanfanercept (HBM9036) in Patients with Moderate-to-Severe Dry Eye Disease in China at the 25th Congress of Chinese Ophthalmol prnasia
November 17, 2020
Harbour BioMed (HBM) announced that the company will present the phase II clinical trial results of Tanfanercept (HBM9036) at the 25th Congress of Chinese Ophthalmological Society (CCOS) held in Xiamen from the 19th to 22nd November.